Darolutamide Takes Root With New Prostate Cancer Benchmark
Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.
Related Articles
T-DXd Wins EU Approval for HR+, HER2-Low or -Ultralow Metastatic Breast Cancer After Endocrine Therapy
The European Commission approved trastuzumab deruxtecan for HR-positive, HER2-low or -ultralow metastatic breast cancer after at least 1 endocrine therapy.
Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL
Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.
Single-Center Experience Highlights Utility of CD19-Directed CAR T-Cell Therapy in B-Cell Malignancies
Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.
Newly Approved ADCs Expand Options in HR+ Metastatic Breast Cancer
Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.
Neoadjuvant Darovasertib Receives FDA Breakthrough Therapy Designation for Uveal Melanoma
Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.
Dr Shadman on the Framework of a Meta Analysis of BTK Inhibitors in R/R CLL
Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R…
Oncology Experts Preview Top Abstracts From AUA 2025
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
Integrating CAR T-Cell Therapy Into the Treatment Landscape for R/R DLBCL
Experts discuss the role of chimeric antigen receptor T-cell therapy (CAR T) in the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), how…
Dr Chmielowski on the Rationale for Investigating Oncolytic Viruses in Melanoma
Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.
Meta Analysis Shows Efficacy Trend Favoring Zanubrutinib in High-Risk R/R CLL
A network meta analysis compared the efficacy of BTK inhibitors in patients with high-risk R/R chronic lymphocytic leukemia.